Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma

The efficacy of sequential everolimus, an orally administered inhibitor of mammalian target of rapamycin (mTOR), was proven in a placebo-controlled phase III study, where median progression-free survival was 4.9 vs 1.9 months for placebo (hazard ratio: 0.33, P < 0.001). Placebo crossovers (80%) c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Maxine, Abdollah, Firas, Schmitges, Jan, Jeldres, Claudio, Shariat, Shahrokh F, Perrotte, Paul, Karakiewicz, Pierre I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818936/
https://www.ncbi.nlm.nih.gov/pubmed/24198635
http://dx.doi.org/10.2147/OAJU.S13283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818936/
https://www.ncbi.nlm.nih.gov/pubmed/24198635
http://dx.doi.org/10.2147/OAJU.S13283

Ejemplares similares